Expanding Immunotherapy to Cervical Cancer
The FDA approved pembrolizumab for patients with recurrent or metastatic cervical cancer that tests positive for PD-L1 and that has progressed despite chemotherapy.
Progress Against Cancer
The FDA approved pembrolizumab for patients with recurrent or metastatic cervical cancer that tests positive for PD-L1 and that has progressed despite chemotherapy.
The FDA expanded the use of the immunotherapy pembrolizumab for certain patients with an aggressive type of non-Hodgkin lymphoma.
Study: Initial treatment with an immune checkpoint inhibitor was associated with longer survival of patients with melanoma that had spread to the brain.
A recent study found that less than 13 percent of baby boomers were screened for the virus despite the recent approval of several effective treatments. Almost half of liver cancer cases in the United...
A study found declines in lung cancer death rates among women in the United States have lagged in two geographic hot spots.
The FDA expanded the use of the CAR T-cell therapy tisagenlecleucel to include certain patients with non-Hodgkin lymphoma.
The FDA approved a combination of the immunotherapeutics to treat certain patients diagnosed with the most common form of kidney cancer.
The FDA approved a combination of molecularly targeted therapeutics for use in combination to treat patients with metastatic non-small cell lung cancer.
Women who work the night shift may have an increased risk of breast, skin, and gastrointestinal cancers, according to a study.
A recent study revealed large variations in colorectal cancer screening rates among states and counties. Colorectal cancer is the fourth most commonly diagnosed cancer in the United States with more than 135,000 diagnoses and...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More